Irlanti - englanti - HPRA (Health Products Regulatory Authority)

sun pharmaceutical industries europe b.v. - warfarin sodium clathrate - tablet - 2 milligram(s) - vitamin k antagonists; warfarin - antithrombotic agent (vitamin k antagonist) - it is indicated for the prophylaxis of venous thrombosis and pulmonary embolism, and for use in the treatment of these conditions to prevent their extension and for the prophylaxis of systemic embolisation in patients with rheumatic heart disease and atrial fibrillation.

Irlanti - englanti - HPRA (Health Products Regulatory Authority)

sun pharmaceutical industries europe b.v. - warfarin sodium clathrate - tablet - 10 milligram(s) - vitamin k antagonists; warfarin - antithrombotic agent (vitamin k antagonist) - it is indicated for the prophylaxis of venous thrombosis and pulmonary embolism, and for use in the treatment of these conditions to prevent their extension and for the prophylaxis of systemic embolisation in patients with rheumatic heart disease and atrial fibrillation.

Irlanti - englanti - HPRA (Health Products Regulatory Authority)

sun pharmaceutical industries europe b.v. - warfarin sodium clathrate - tablet - 7.5 milligram(s) - vitamin k antagonists; warfarin - antithrombotic agent (vitamin k antagonist) - it is indicated for the prophylaxis of venous thrombosis and pulmonary embolism, and for use in the treatment of these conditions to prevent their extension and for the prophylaxis of systemic embolisation in patients with rheumatic heart disease and atrial fibrillation.

Irlanti - englanti - HPRA (Health Products Regulatory Authority)

sun pharmaceutical industries europe b.v. - warfarin sodium clathrate - tablet - 6 milligram(s) - vitamin k antagonists; warfarin - antithrombotic agent (vitamin k antagonist) - it is indicated for the prophylaxis of venous thrombosis and pulmonary embolism, and for use in the treatment of these conditions to prevent their extension and for the prophylaxis of systemic embolisation in patients with rheumatic heart disease and atrial fibrillation.

Irlanti - englanti - HPRA (Health Products Regulatory Authority)

sun pharmaceutical industries europe b.v. - warfarin sodium clathrate - tablet - 5 milligram(s) - vitamin k antagonists; warfarin - antithrombotic agent (vitamin k antagonist) - it is indicated for the prophylaxis of venous thrombosis and pulmonary embolism, and for use in the treatment of these conditions to prevent their extension and for the prophylaxis of systemic embolisation in patients with rheumatic heart disease and atrial fibrillation.

Irlanti - englanti - HPRA (Health Products Regulatory Authority)

sun pharmaceutical industries europe b.v. - warfarin sodium clathrate - tablet - 3 milligram(s) - vitamin k antagonists; warfarin - antithrombotic agent (vitamin k antagonist) - it is indicated for the prophylaxis of venous thrombosis and pulmonary embolism, and for use in the treatment of these conditions to prevent their extension and for the prophylaxis of systemic embolisation in patients with rheumatic heart disease and atrial fibrillation.

Euroopan unioni - englanti - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sonidegib diphosphate - carcinoma, basal cell - antineoplastic agents - odomzo is indicated for the treatment of adult patients with locally advanced basal cell carcinoma (bcc) who are not amenable to curative surgery or radiation therapy.

Yhdistynyt kuningaskunta - englanti - MHRA (Medicines & Healthcare Products Regulatory Agency)

sun pharmaceutical industries europe b.v. - warfarin sodium - oral tablet - 1mg

Yhdistynyt kuningaskunta - englanti - MHRA (Medicines & Healthcare Products Regulatory Agency)

sun pharmaceutical industries europe b.v. - warfarin sodium - oral tablet - 3mg

Australia - englanti - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - levetiracetam, quantity: 100 mg/ml - injection, concentrated - excipient ingredients: glacial acetic acid; water for injections; sodium chloride; sodium acetate trihydrate - levetiracetam (film-coated tablets and oral solution) is indicated for:,? use in epileptic patients aged 4 years and older, initially as add on therapy, in the treatment of partial onset seizures with or without secondary generalisation, ? monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy. ? add on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme),and ? add on therapy in the treatment of primary generalized tonic-clonic seizures in adults and children from 4 years of age with idiopathic generalized epilepsy (ige).,levetiracetam sun concentrated injection after dilution is an alternative for patients when oral administration is temporarily not feasible.